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Purpose: To analyze the cost and detection rate of a screening program for detecting glaucoma 
with imaging devices.
Materials and methods: In this cross-sectional study, a glaucoma screening program was 
applied in a population-based sample randomly selected from a population of 23,527. Screen-
ing targeted the population at risk of glaucoma. Examinations included optic disk tomography 
(Heidelberg retina tomograph [HRT]), nerve fiber analysis, and tonometry. Subjects who met 
at least 2 of 3 endpoints (HRT outside normal limits, nerve fiber index 30, or tonometry 21 
mmHg) were referred for glaucoma consultation. The currently established (“conventional”) 
detection method was evaluated by recording data from primary care and ophthalmic consul-
tations in the same population. The direct costs of screening and conventional detection were 
calculated by adding the unit costs generated during the diagnostic process. The detection rate 
of new glaucoma cases was assessed.
Results: The screening program evaluated 414 subjects; 32 cases were referred for glaucoma 
consultation, 7 had glaucoma, and 10 had probable glaucoma. The current detection method 
assessed 677 glaucoma suspects in the population, of whom 29 were diagnosed with glaucoma 
or probable glaucoma. Glaucoma screening and the conventional detection method had detec-
tion rates of 4.1% and 3.1%, respectively, and the cost per case detected was 1,410 and 1,435€, 
respectively. The cost of screening 1 million inhabitants would be 5.1 million euros and would 
allow the detection of 4,715 new cases.
Conclusion: The proposed screening method directed at population at risk allows a detection 
rate of 4.1% and a cost of 1,410 per case detected.
Keywords: screening, glaucoma, cost, imaging devices, detection rate
Introduction
Glaucoma meets some of the criteria recommended by the World Health Organization 
in order to consider screening programs useful and cost-effective. It has been esti-
mated that 67% of affected individuals are undetected in the UK1 and 71% in Spain.2 
However, selective screening of groups with a higher disease prevalence based on 
age, African ethnicity, and family history could be worthwhile. Burr et al predicted 
that screening could be cost-effective in a 50-year-old cohort at a prevalence of 4% 
with at least a 2-year screening interval.1
Similarly, the question of which tests should be used to screen for glaucoma has 
no definite, scientifically proven, or even a consensus answer.3 Intraocular pressure 
is usually included in screening protocols associated with other tests to identify the 
most important risk factor, even though it has little value as a diagnostic test for 
glaucoma. Short functional tests of different kinds have proved useful for glaucoma 
screening, but they all have relevant disadvantages including a relatively long testing 
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time (one to several minutes) and the learning effect. These 
are particularly important for screening programs targeting 
a perimetrically inexperienced population. All functional 
tests require the subjects’ active participation and repeated 
examinations4 to overcome the learning effect. They fre-
quently show high false-positive classification rates.3–6 For 
these reasons no functional test was used in this study.
An option increasingly used for screening is the acquisition 
of optic nerve and/or retinal nerve fiber layer photographs or 
images. Photographs are easily obtained with non-mydriatic 
cameras in seconds in most subjects. Even easier is the acquisi-
tion of images with scanning laser ophthalmoscopy (Heidel-
berg retina tomograph [HRT]), scanning laser polarimetry 
(Nerve fiber analyzer [GDx]), or optical coherence tomography 
(OCT), and there are many reports indicating their usefulness 
for glaucoma diagnosis.3,7–9 Photographs require subjective 
physician evaluation, whereas imaging devices allow automatic 
classification of cases and results can be sent anywhere as a 
small pdf file. Physician supervision may be reduced to quality 
control and confirmation of abnormal imaging results, which 
may significantly decrease assessment time and cost. De Mul 
et al showed that GDx images obtained and filtered by optom-
etrists are useful for glaucoma screening by telemedicine,10 
while Blazquez et al,11 Ohkubo et al,8 and Toth et al9 reported 
the usefulness of HRT for glaucoma screening.
Finally, the literature on costs and effectiveness of 
screening for glaucoma, particularly with imaging devices, is 
limited. A systematic review of cost-effectiveness of screen-
ing strategies for open-angle glaucoma (OAG) reported the 
absence of sufficient economic evidence for determining if 
screening for OAG should be performed and, if it should, 
then how should it be performed.12
The goal of the current study was to analyze the cost 
and the detection rate of a screening program for detecting 
glaucoma based on imaging devices.
Materials and methods
Design
This was a cross-sectional population-based study. Costs and 
detection rate of a screening program and also those of current 
conventional detection used by the Sistema Nacional de Salud 
(the Spanish National Health System, NHS) were assessed in 
the same population but in different specific samples. Only 
cases newly diagnosed by one of the 2 detection methods 
were considered for all calculations.
study population and samples
The study population comprised 23,527 subjects 40 years 
of age included in the census of the primary care center (PCC) 
CAP Larrard (Barcelona, Spain). The sample to evaluate 
glaucoma screening comprised 1,600 subjects randomly 
selected from this population. This number was estimated 
as sufficient to reach the 343 subjects required according to 
sample size calculation (see below), taking into consideration 
that health registers are sometimes incomplete or outdated, 
and an expected 50% participation rate. Of those 1,600, 
1 subject was duplicated and 36 were deceased, so the initial 
study sample included 1,563 subjects. To assess conven-
tional detection, the sample comprised all patients visiting 
primary care physicians for any ophthalmic reason and/or 
attending ophthalmic consultation at the PCCs (a general 
ophthalmologist sees patients at the PCC) during the study 
period. These data were obtained from the electronic medical 
records of all 23,527 subjects in the population.
sample size calculation
Sample size was calculated from prevalence rates of glau-
coma and ocular hypertension (OH) of 2.1% and 1.6%,2 
respectively, and an estimated rate of undiagnosed cases of 
70%. Assuming an alpha risk of 0.05, an accuracy of ±0.02%, 
and for an estimated proportion of 0.037 (this figure comes 
from adding prevalence of glaucoma [0.021] and OH [0.016] 
in Spain), a sample of at least 343 subjects evaluated by each 
detection method was required to identify differences in the 
cost and the detection rate between conventional detection 
and the screening program.
glaucoma screening
Contact with participants
The screening program was advertised at the PCC and all 
subjects received a phone call during which the study was 
explained, the presence or absence of glaucoma risk factors was 
initially evaluated with a brief questionnaire, initial oral consent 
was requested, and a visit was scheduled. In cases of doubt 
concerning inclusion criteria, the subject was also scheduled for 
examination. A minimum of 3 calls at different times of the day 
were made before subjects were considered unreachable.
subjects
The screening program targeted subjects at risk for glaucoma 
with one of the following conditions: age 60 years 
or 40 years with at least one other risk factor (personal 
history of OH, family history of glaucoma, myopia exceed-
ing 3 diopters, or African ethnicity).
examinations
Subjects who met the inclusion criteria were evaluated at 
the PCC after giving their written informed consent. One 
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optometrist and 4 ophthalmic nurses experienced in image 
acquisition were specifically trained for this study (20 hours 
of training sessions). They measured visual acuity, admin-
istered a health questionnaire, confirmed inclusion criteria, 
acquired HRT-3 images (Heidelberg Engineering, Heidel-
berg, Germany), GDx-VCC images (Carl Zeiss Meditec, 
Dublin, CA, USA), and performed rebound tonometry (Icare, 
Icare Finland Oy, Espoo, Finland).
Data analysis
Only good quality images were considered and used to clas-
sify subjects. The HRT-III images had to be of “fair” or better 
quality (good, very good, or excellent), with topographic 
standard deviation 40 µ, centered, and sharp. Images were 
considered abnormal if the global Moorfields regression 
analysis (MRA) was borderline or outside the normal limits. 
GDx-VCC images had a quality index Q of 6 or better and 
were centered and sharp. Images were considered outside the 
normal limits if the nerve fiber index (NFI) was 30.
Definitions and classification
Screening was considered positive if at least 2 of the follow-
ing criteria were met in at least 1 eye: intraocular pressure 
(IOP) 21 mmHg, HRT outside the normal limits, and/or 
GDx-VCC outside the normal limits. The screening result 
was considered negative in all other cases or combination 
of results (Figure 1). Nevertheless, when both images were 
normal and the IOP was 21 mmHg, the patient was clas-
sified as ocular hypertensive and was not scheduled for 
glaucoma consultation within the study protocol but was 
recommended repeated ophthalmic visits at the PCC. The 
protocol specified that IOP values 30 mmHg should be sent 
within 24 hours for ophthalmic consultation at the hospital, 
but no such cases were found. Images were initially evaluated 
by nurses and optometrists at the PCC, captured by a tele-
medicine application and sent to the referral hospital where 
a glaucoma specialist reviewed all positive cases and 10% of 
negative cases. The latter was performed as a quality check. 
Subjects classified as positive were referred to glaucoma 
consultation. Subjects classified as negative at screening 
but having high IOP were classified as OH. Together with 
those identified by nurses/optometrists as suspected of hav-
ing some other eye disease, they were advised to schedule 
an ophthalmic consultation.
Conventional detection
Current glaucoma detection within the Spanish NHS occurs 
via primary care doctors, optometrists, and ophthalmolo-
gists when a patient decides to visit them. In order to esti-
mate the cost and the detection rate of this “conventional 
detection” process, data were included from the electronic 
medical records of all subjects 40 years of age referred to 
the ophthalmologists at the PCC for glaucoma, suspected 
glaucoma, OH, or a positive family history of glaucoma, 
together with those who were diagnosed with any of these 
pathologies. This took place the year before the screening 
campaign was performed, in order to avoid the positive influ-
ence of advertisements and brochures about glaucoma on 
conventional detection. A total of 932 subjects initially met 
the criteria, of whom 255 were not evaluated by a primary 
care physician and not referred for ophthalmic consulta-
tion for different reasons (already diagnosed and followed 
up elsewhere or risk factors not confirmed). Age, gender, 
ophthalmic history, reason for referral, and results of the 
ophthalmic visits at the PCC and the hospital were recorded 
and analyzed. Patients detected during the study underwent 
glaucoma consultation at the hospital (Figure 2).
glaucoma consultation
The goal of the glaucoma consultation was to confirm or rule 
out the diagnosis of glaucoma with the following tests: refrac-
tion, Goldman tonometry, Humphrey 24–2 Swedish interac-
tive threshold algorithm (SITA) standard fields, gonioscopy, 
optic disc photography, and an examination of the anterior 
and posterior segments performed by an experienced 
glaucoma expert (Alfonso Anton, AA). The examinations 
were performed at the referral hospital. HRT and GDx images 
acquired at screening were also available for the glaucoma 
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Figure 1 Definition of positive and negative results at screening.
Note: A positive result was defined as the presence of at least 2 tests outside 
normal limits.
Abbreviations: iOP, intraocular pressure; hrT, heidelberg retina tomograph; 
Onls, outside normal limits.
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consultant. Patients were classified as normal or with OH, 
probable glaucoma, or glaucoma according to the criteria 
shown in Table 1. The degree of glaucoma at diagnosis was 
established according to the mean deviation in the worse 
eye. Patients were classified as having early, moderate, or 
advanced glaucoma if the mean deviation (Humphrey SITA 
standard fields) was between 0 and −6 dB, ranged from −6 
to −15 dB, or was −15 dB, respectively.
Detection rate
The detection rate was calculated by dividing the number 
of new cases identified during the study by the total number 
of cases examined.
Cost assessment and sensitivity analysis
The cost was calculated by adding the unit costs of all 
resources used in the different activities occurring during the 
diagnostic process. This process included all activities and 
procedures performed to detect cases with glaucoma from the 
first visit or the invitation to participate in the screening cam-
paign to the moment when the ophthalmologist established 
the diagnosis. The criteria used were based on the concept of 
activity-based costing. This method was specifically applied 
for this study at the PCC, while in the Hospital we used a stan-
dardized cost-accounting system.13,14 Costs included health 
professionals, devices, and infrastructure at the PCC and 
the hospital. Personnel costs were calculated from the total 
cost of each professional participating in a certain activity 
according to the time specifically dedicated to that particular 
activity. For example, nurses or optometrists who performed 
the screening dedicated 12 of 35 hours of their weekly work 
time to the diagnostic process and only that part of their full 
salary was considered a cost. For doctors, who performed 
different tasks (training, examination, or test interpretation), 
only the cost of the fraction of their work time dedicated to 
the specific task involved in the glaucoma diagnostic process 
was added. The costs of the devices and materials (GDx-
VCC, HRT, tonometer, ophthalmoscope, retinograph, and 
lenses) were calculated based on a 5-year amortization and 
the total number of tests performed annually. The costs of 
disposable materials used in the ophthalmic visits (eye drops 
and tissues) were also added. The fixed (or structural) costs at 
the PCC (electricity, water, gas, maintenance, and security) 
were estimated from the global structural costs of the facility 
divided by the total number of patients seen and multiplied by 
the number of patients evaluated in the detection process. The 
structural costs at the hospital (glaucoma consultation) were 
taken from the hospital cost-accounting system,13,14 which 
calculates structural costs for each department related to the 
consumption of resources. The fixed costs computed for the 
Department of Ophthalmology comprise an additional 20% 
of the cost of each activity.
Costs calculated for the screening program were based 
on its application to the study sample. As costs may vary 
significantly depending on the size of the target population 
and other factors, a sensitivity analysis was performed. 
First, costs were also calculated considering a mean of the 
detection rate calculated by other studies (4.9%)8,9,27 using 
the same imaging devices. Second, the costs of screening in 
the population were recalculated through the activity that 
would be generated by the implementation of the screening 
program studied in the NHS in a community of 1 million 
subjects. This calculation was performed using the participa-
tion and detection rates obtained in this study and assuming 
that 1 nurse, 1 optometrist, and 1 assistant could perform the 
telemedicine screening program at the PPC. This framework 
proved both feasible and effective for this study. Finally, the 
cost per case detected was calculated by dividing the total 
cost of all cases detected by the number of cases detected by 
each detection method.
ethics
The study was approved by the Research Commission and 
the Ethics Committee of the Parc de Salut Mar. The study 
complied with the tenets of the Declaration of Helsinki.
Results
Of the sample selected (n=1,563) for glaucoma screen-
ing, 626 (40%) subjects could not be reached, 181 (12%) 
were located but did not meet the risk criteria, and 756 
(48%) met the risk criteria. Of the latter, 342 (45%) did 
not want to participate and in 19, the reason was that they 
already had been diagnosed with glaucoma. The participa-
tion rate among those reached and meeting the criteria was 
Table 1 Classification criteria
Diagnosis IOP (mmHg) Optic disc Visual field
normal 22 normal normal
Oh 22 normal normal
Probable glaucoma any glaucomatousb normal
any normal glaucomatousa
glaucoma any glaucomatousb glaucomatousa
Notes: aGlaucomatous field: 3 contiguous locations outside normal limits in the 
pattern deviation plot. bglaucomatous optic disc: presence of rim thinning, and/
or cup/disk asymmetry of 0.3 and/or disk hemorrhage and/or nerve fiber layer 
defect. Based on direct examination at the slit lamp, disk photographs, hrT, and 
gDx images.
Abbreviations: GDx, nerve fiber analyzer; HRT, Heidelberg retina tomograph; 
iOP, intraocular pressure; Oh, ocular hypertension.
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55% (414/756; Figure 2). Demographic characteristics are 
shown in Table 2. A total of 932 subjects from the same 
population underwent conventional evaluation the year 
before the screening was performed.
glaucoma screening
Of the 414 subjects who completed the screening program, 
13 subjects (3.1%) had an IOP 21 mmHg in at least 1 eye 
and in 7 of them the pressure was high bilaterally. The mean 
IOP ± standard deviation was 14.5±3.7 mmHg (range, 7–30). 
Good-quality HRT images could not be obtained in 53 eyes 
(6.4%), the MRA was normal in 602 eyes (72.7%), and 
outside the normal limits or borderline in 173 eyes (20.3%). 
Obtaining good-quality GDx images was unfeasible in 69 
eyes (8.3%), while the NFI was normal in 666 eyes (80.5%) 
and abnormal in 93 eyes (11.2%). Thirty-two subjects (7.7%) 
were classified as positive at screening (Figure 2).
Additionally, glaucoma screening identified 31 subjects 
with other ophthalmic pathologies different from glaucoma, 
7 tested negative in glaucoma screening but were also referred 
for ophthalmic consultation. The other 24 resulted positive 
during the screening process. Pathologies identified included 
15 cataracts, 6 myopias, 2 age-related macular degenera-
tions, and only 1 case of several diseases (blepharitis, retinal 
toxoplasma scars, retinal detachment, scleromalacia, ptosis, 
band queratopathy, non-proliferative diabetic retinopathy, 
and lens subluxation).
Conventional detection
Figure 2 shows the distribution of all subjects evaluated 
(n=932) for glaucoma at the PCC or who were suspected 
of having the disease. Of the 932 individuals evaluated 
by the primary care doctor, 255 were evaluated only by 
the primary care physician, 677 were referred to a general 
ophthalmologist at the PCC, and 51 were newly diagnosed 
with glaucoma or suspected glaucoma and required ophthal-
mic testing (Figure 2). The conventional detection method 
also identified 41 cases with other pathologies including 26 
blepharitis, 5 cataracts, 2 cases with pathologic myopia, 2 
with non-proliferative diabetic retinopathy, 2 with age-related 
macular degeneration, and 1 case of several pathologies 
(floppy eyelid, cornea guttata, pterigion, vascular sclerosis, 
and retinoschisis).
glaucoma consultation
The 32 subjects who were positive at the screening program 
were invited to attend a glaucoma consultation. Eight did 
not want to continue the study (6 were seeing another 
glaucoma specialist and 2 did not specify a reason) and 
24 completed the glaucoma visit. Six were normal, 7 were 
diagnosed with glaucoma, 10 were classified as having 
probable glaucoma, and 1 had OH. Five of the 7 glaucoma 
cases were primary OAG, 1 had primary angle-closure 
glaucoma, and 2 pseudoexfoliation glaucoma. The latter 
was also the only patient in the sample who had high IOP 
and both images (HRT and GDx) outside the normal limits 
(Figure 1).
Of the 51 subjects identified by the conventional exami-
nation in the population, 6 were normal, 16 had OH, 20 had 
probable glaucoma, and 9 were diagnosed with definite glau-
coma (6 primary OAG, 2 primary angle-closure glaucoma, 
and 1 pseudoexfoliation glaucoma).
Table 2 Demographics of the participants
Variable Population Randomly selected 
screening sample
Subjects included and 
examined at screening 
program (randomly 
selected and invited 
to participate)
Subjects examined by 
current detection method 
(belong to same population 
but entered the detection 
process spontaneously with 
no prior selection)
subjects 40 years 23,527 1,599 414 165
age (years) mean ± sD (range) 63.37±10.61 (40–100) 63.29±14.73 (40–100) 65.2±11 (40–93) 70.2±9.8 (43–94)
40–49 (%) 5,256 (22.3) 358 (22.4) 50 (12.0) 8 (4.8)
50–59 (%) 4,947 (21.0) 336 (21.0) 69 (16.7) 12 (7.3)
60–69 (%) 4,886 (20.8) 332 (20.7) 135 (32.6) 52 (31.5)
70–79 (%) 4,361 (18.5) 297 (18.5) 107 (25.9) 64 (38.8)
80–89 (%) 3,226 (13.7) 219 (13.6) 52 (12.6) 28 (17.0)
90–99 (%) 851 (3.6) 58 (3.6) 1 (0.2) 1 (0.6)
gender (%)
Women 14,155 (60.2) 986 (61.6) 249 (60.1) 106 (64.2)
Men 9,372 (39.8) 613 (38.3) 165 (39.9) 59 (35.8)
Abbreviation: sD, standard deviation.
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The detection rates of cases with glaucoma or probable 
glaucoma (both considered new cases) were 3.1% and 
4.1%, respectively, for conventional detection and glau-
coma screening with imaging devices. Table 3 shows the 
severity of glaucoma in the cases diagnosed using both 
detection methods. The visual field parameters of the cases 
identified indicated that the screening program tended to 
detect glaucoma with less functional damage than the cases 
diagnosed conventionally, although the difference was not 
statistically significant, probably due to the low number of 
cases detected.
Costs
The individual cost of each activity is shown in Table 4. Costs 
of the primary care visit, ophthalmic visit at PPC, ophthalmic 
visit with testing, glaucoma screening, and glaucoma consul-
tation were 15, 18, 52, 50, and 126€, respectively (Table 5). 
The cost of screening could be reduced from 50 to 38€ per 
patient screened if applied to a population of 1 million by 
implementing a full-time screening program. This reduc-
tion is possible if the screening program is fully functional 
throughout the year and the costs of health professionals 
and infrastructure, but particularly those of the devices, can 
be distributed over a far greater number of cases evaluated.
The cost per case detected (Table 6) was similar for 
conventional detection (1,435€) and the screening program 
(1,410€). Sensitivity analysis revealed low to moderate 
modifications of the costs of the screening program. Costs 
would not have varied significantly if a mean of the detec-
tion rate calculated by other studies (4.9%)8,9,27 using the 
same imaging devices was used to calculate cost per case 
detected. For the detection rate of 4.9%, the cost per case 
detected by screening would have been 1,238€. Additionally, 
in the hypothetical setting of a fully implemented screening 
program directed at all inhabitants at risk for glaucoma in a 
population of 1 million subjects, the cost per case detected 
would be 1,121€.
Sensitivity analysis revealed moderate modifications of 
the cost-effectiveness of the screening program. If detection 
Table 3 Degree of glaucoma in detected cases
Variable Screening  
program
Conventional 
detection
Mean deviation (range) −3.54±2.63  
(−10.31 to −0.14)
−5.52±7.18  
(−25 to 0)
Visual field index (range) 97.85±2.20  
(94 to 100)
81.92±21.32  
(25 to 100)
Degree of glaucoma according to mean defect (dB)
initial, 0 to −6 15 (88.23%) 14 (56%)
Moderate, −6.1 to −15 2 (11.77%) 5 (20%)
advanced, −15.1 – 6 (24%)
Table 4 estimated individual costs
Type of exam/location Activity Cost (€)
Primary care center admission/reception 3.57
Primary care visit 10.18
structural cost 1.96
Ophthalmology at primary 
care center
admission/reception 3.57
Optometry visit 5.43
Ophthalmology visit  
(including material)
6.23
structural cost 1.96
glaucoma screening at 
primary care centera
examination  
(technician and nurse)
31.37
instruments 10.69
Training subject information 8.54
glaucoma visit at hospital glaucoma consultationb  
(includes infrastructure =20%)
55.41
Fundus photograph 37.44
Visual field 15.94
Pachymetry 17.74
Notes: aThis cost was calculated by optimizing the use of instruments and staff for a 
larger scale screening program. bData obtained from previous costs calculations.13,14
Table 5 Cost of glaucoma screening and conventional detection
Variable Screening  
in selected  
sample
Estimated  
screening  
in 1 million
Conventional 
detection  
in population
sample/population
subjects 1,563 1,000,000 46,838
Cases examined
subjects 414 502,305 932
Primary care visits
subjects 130,052 932
Cost/visit 15.70
Total cost 14,632.4
Ophthalmic visit at primary care
subjects 677
Cost/visit 18.69
Total cost 12,653.13
Ophthalmic visit at primary care with tests  
(visual field + optic disc photograph)
subjects 165
Cost/visit 52.37
Total cost 8,641.05
screening program visits at primary care centre with tests (hrT, gDx)
subjects 414 130,052
Cost/visit 50.60 38.7
Total cost 20,946.90 5,036,949.4
glaucoma consultations at hospital with tests  
(visual field + optic disc photograph + gonioscopy)
subjects 24 7,539 45
Cost/visit 126.53 126,5 126.53
Total cost 3,036.72 954,022.9 5,693.85
Total cost 23,983.62 5,990,972.3 41,620.43
Abbreviations: GDx, nerve fiber analyzer; HRT, Heidelberg retina tomograph.
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rates from previous studies using HRT and GDx were used 
for calculations, the cost per case detected decreased to 
1,238€. In a hypothetical setting where the screening program 
would be performed full time and directed at a population 
of 1 million subjects, the cost per case detected would be 
1,121€.
Discussion
In Spain, as in many other developed countries, the health 
system fails to detect all glaucoma-affected patients. Imaging 
devices and a technology-based first assessment, as in the 
current study, could improve the number of cases detected 
while reducing screening costs. We used tonometry and 2 
different imaging devices, avoiding functional tests, for 4 
reasons. First, to shorten the testing time and to avoid the 
learning effect and inevitable repetition of functional tests, 
which are particularly relevant among inexperienced sub-
jects. Second, tonometry and the 2 imaging devices are easy 
to transport to a remote screening center far from specialized 
clinics. Third, all 3 tests are easy to use and data acquisi-
tion is rapid. Finally, both imaging devices allow automatic 
classification using thoroughly evaluated algorithms with 
good sensitivity and specificity.9,15–19 HRT sensitivity and 
specificity were 72.3%–91.5% and 84.0%–93.1% in a similar 
setting evaluated by Ohkubo et al.8 In a study with Reus et 
al, we observed that GDx and HRT outperformed European 
Ophthalmologists when classifying optic nerves. GDx-VCC 
nerve fiber indicator and the HRT best classifier correctly 
classified 93.2% and 89.9% of eyes, respectively.20 Toth 
et al observed that screening for glaucoma with GDx-VCC 
or HRT offers a sensitivity of 89.5% and 42%–92% and a 
specificity of 96.8% and 60%–82%, respectively.9
The detection rate of 4.1% obtained with screening was 
similar to that found by Ohkubo et al (3.9%) using only 
HRT8 and de Mul et al10 (4.6%) using only GDx. Neverthe-
less, the detection rate was slightly lower than the 6.2% rate 
Table 6 Detection rate and cost per case detected
Variable Screening with 
imaging devices 
(sample)
Screening applied in the NHS 
to 1 million subjects. Screening 
examination cost of 38.7€/persona
Conventional 
detection 
(population)
Population 1,000,000 46,838
Population 40 years 1,563 502,305 23,527
subjects examined (a) 414 130,052 932
glaucoma cases detected (B) 17 5,340 29
glaucoma detection rate (B/a) 4.1 4.1 3.1
Total cost (C) 23,983.6 5,990,972.3a 41,620
Cost/case detected (C/B) 1,410.8 1,121.8 1,435.1
Notes: aThis cost was calculated by optimizing the use of instruments and staff for a larger scale screening program. B: cases classified as glaucoma or probable glaucoma.
Abbreviation: nhs, national health survey.
reported by Toth et al who used HRT and GDx in a smaller 
study.9 The detection rate with conventional detection was 
3.1%, 1% lower than that obtained by active screening in 
this study. However, the cases identified by the screening 
program were characterized by a lesser degree of functional 
damage, including 88% of initial cases vs only 56% identi-
fied by conventional detection (Table 3). Quality of life has 
been shown to be significantly correlated with the degree 
of visual field damage,21 and initial field abnormalities have 
been associated empirically and by mathematical models 
to a reduced loss of the quality-adjusted life years (QALY) 
compared with more advanced cases.22
The non-acceptance to participate rate in the screening 
program was 36%, a certainly high figure but comparable 
to that observed in other population-based studies and it is 
unlikely that it significantly influenced the results because 
the distribution in age groups of the sample is similar to that 
of the population (Table 2) with the only exception of the 
people with ages from 40 to 49 years (smaller percentage in 
the sample than in the population) who have relatively low 
prevalence of glaucoma.2
Cost calculation is complex and affected by multiple 
factors, varying significantly among different countries and 
settings. The estimated cost for a first visit to a glaucoma 
specialist including tests in the NHS in Spain was 126€ 
($137), while Schmier et al and Fremont et al estimated $582 
in Canada.23,24 Moreover, our study confirmed that the cost 
of screening is significantly affected by the scale and utiliza-
tion of the service. The cost per case examined and the cost 
per case detected decreased from 50 to 38€ and from 1,410 
to 1,211€, respectively, if screening was applied in a large 
population. The latter is slightly higher than the mean cost 
of 922$ estimated by a meta-analysis on telemedicine glau-
coma screening with photographs25 and lower than the cost 
of 2,561$ per case computed by Blumberg et al using OCT.26 
Also, costs would have not varied significantly if a mean 
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to 1,121€ if applied to large populations. The incremental 
cost of screening for glaucoma in a population of 1 million 
inhabitants would be 5.1€ million but would also allow the 
detection of 4,715 new cases.
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